Drugs / PP-01
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05494437 | Oct 2022 → Aug 2023 | substance withdrawal syndrome | PleoPharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07644052 | Jun 2026 → Jul 2027 expected | substance withdrawal syndrome | PleoPharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05494437 ↗ |
| Action | Activate | “Cannabinoid-1 (CB1) partial agonist” NCT05494437 ↗ |
| Route | Oral | “Oral PP-01 High Dose tapered/titrated over 34 days” NCT05494437 ↗ |